Revista Española de Quimioterapia,
Год журнала:
2023,
Номер
36(Suppl1), С. 18 - 21
Опубликована: Ноя. 24, 2023
The
SARS-CoV-2
infection
prognosis
has
dramatically
changed
as
a
result
of
population
vaccination
and
the
surge
omicron.
However,
there
are
still
specific
populations
at
risk
progression
to
severe
diseases
that
require
hospitalization
or
even
death.
kidney
transplant
is
one
them.
Consequently,
when
compatible
symptoms
appear,
an
early
diagnosis
should
be
sought
in
order
start
antiviral
treatment
soon
possible
avoid
clinical
deterioration
patient.
Antivirals
have
shown,
patients,
decrease
rate
death,
especially
with
their
administration.
Transplant Infectious Disease,
Год журнала:
2023,
Номер
25(5)
Опубликована: Авг. 16, 2023
Since
November
2020,
Italy
was
the
first
country
to
carry
out
a
protocol
and
use
liver
from
COVID-19
donors.
We
aimed
evaluate
medium-term
outcome
of
patients
who
underwent
transplant
(LT)
with
those
grafts.We
consecutively
enrolled
283
LT
2020
December
2022
in
our
Center
(follow-up
468
days).
Twenty-five
(8.8%,
study
population)
received
graft
donors
previous
(4%)
or
active
(96%)
SARS-CoV-2
infection,
258/283
(91.2%,
control
group)
COVID-19-negative
SARS-CoV-2-RNA
tested
on
tissue
their
recipients
weekly
evaluation
nasal
swabs
for
month
after
LT.One-year
2-year
patient
survival
88.5%
group
versus
94.5%
93.5%
group,
respectively
(p
=
.531).
In
population
there
no
evidence
donor-recipient
virus
transmission,
but
three
(12%)
(vs.
7
[2.7%]
p
.048)
developed
hepatic
artery
thrombosis
(HAT):
they
were
negative
at
1/3
grafts
positive
tissue.
donor
independently
associated
HAT
(odds
ratio
(OR)
4.85,
95%
confidence
interval
(CI)
1.10-19.15;
.037).
By
comparing
acute
rejection
biliary
complication
rates
not
significantly
different
(16%
vs.
8.1%,
.26;
16%
16.3%
.99,
respectively).Our
1-year
results
strategy
including
favorable.
only
higher
rate
transplanted
compared
group.
Frontiers in Pediatrics,
Год журнала:
2023,
Номер
11
Опубликована: Окт. 4, 2023
Prevention
of
donor-derived
disease
among
pediatric
solid
organ
transplant
recipients
requires
judicious
risk-benefit
assessment.
Comprehensive
guidelines
outline
specific
donor
risk
factors
and
post-transplant
monitoring
strategies
to
prevent
mitigate
transmission
HIV,
hepatitis
B,
C.
However,
elimination
unanticipated
infections
remains
challenging.
The
objectives
this
review
are
(1)
define
anticipated
vs.
events
in
recipients;
(2)
discuss
presentations
that
confer
greater
transmission;
(3)
develop
a
matrix
for
consideration
acceptance;
(4)
limitations
future
directions
screening.
Although
confers
inherent
infection
transmission,
the
significant
may
be
mitigated
by
comprehensive
approach
including
assessment,
recipient
need,
monitoring,
early
intervention.
Transplant Infectious Disease,
Год журнала:
2024,
Номер
26(2)
Опубликована: Янв. 8, 2024
Abstract
Background
The
COVID‐19
pandemic
presented
a
significant
challenge
for
Organ
Procurement
Organizations
(OPOs)
with
the
use
of
SARS‐CoV‐2
positive
donors
varying
widely.
This
study
used
detailed
single
OPO
data
to
determine
success
using
donors.
Methods
We
performed
retrospective
cohort
including
all
referred
Gift
Life
from
January
1,
2021,
June
30,
2023.
Descriptive
analyses
were
characterize
referral
and
organ
utilization.
Results
There
861
referrals
1
SARS‐Cov‐2
test:
282
ruled
out
telephone
evaluation,
431
onsite
evaluation
(“evaluated
nondonors”)
148
became
For
who
had
both
nasopharyngeal
lower
respiratory
testing
completed,
there
was
notable
result
discordance
observed.
Median
cycle
threshold
(Ct)
values
similar
between
evaluated
nondonors
no
change
in
median
donor
Ct
over
period.
Transplanted
organs
COVID‐positive
included
27
hearts,
88
livers,
5
pancreata,
107
kidneys;
lung
donation
occurred.
proportion
significantly
increased
Conclusion
large
volume
demonstrates
increasing
progressing
time,
supporting
these
nonlung
transplantation.
image
